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Abstract
High-grade serous ovarian cancer (HGSOC) likely originates from
the fallopian tube (FT) epithelium. Here, we established 15 orga-
noid lines from HGSOC primary tumor deposits that closely match
the mutational profile and phenotype of the parental tumor. We
found that Wnt pathway activation leads to growth arrest of these
cancer organoids. Moreover, active BMP signaling is almost always
required for the generation of HGSOC organoids, while healthy
fallopian tube organoids depend on BMP suppression by Noggin.
Fallopian tube organoids modified by stable shRNA knockdown of
p53, PTEN, and retinoblastoma protein (RB) also require a low-Wnt
environment for long-term growth, while fallopian tube organoid
medium triggers growth arrest. Thus, early changes in the stem
cell niche environment are needed to support outgrowth of these
genetically altered cells. Indeed, comparative analysis of gene
expression pattern and phenotypes of normal vs. loss-of-function
organoids confirmed that depletion of tumor suppressors triggers
changes in the regulation of stemness and differentiation.
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Introduction
High-grade serous ovarian cancer (HGSOC), an occult malignancy
which represents 70% of all ovarian cancer cases and has the high-
est mortality rates (5-year survival rate 30–40%) (Reid et al, 2017),
represents a major clinical challenge. Aside from the difficulties in
developing new lines of targeted treatments, late detection and lack
of understanding of the molecular mechanisms that drive develop-
ment of the disease remain major hurdles. Studies in BRCA1/2 germ-
line mutation carriers undergoing prophylactic cancer risk-reducing
surgery (Leeper et al, 2002; Callahan et al, 2007) identified distinct
early malignant changes in the distal part of the FT, leading to wide-
spread acceptance of the theory that the FT is the primary tissue of
origin of HGSOC (Vaughan et al, 2011; Bowtell et al, 2015). These
lesions, termed small tubal intraepithelial carcinoma (STIC), are also
routinely detected in the FT epithelium of ~ 50% of patients at an
advanced stage of the disease and were shown to have the same
genomic profile as the mature cancer—indicative of a clonal rela-
tionship (Kuhn et al, 2012). Nevertheless, all tumor samples genom-
ically and transcriptionally cluster together and closely resemble
tubal epithelium, irrespective of whether STICs were detected in the
FT (Ducie et al, 2017). Therefore, it remains unclear how cellular
transformation occurs, and most importantly, which factors are
essential for the development of invasive and metastatic properties,
which are necessary for the spread of malignant cells from the FT to
the ovary and beyond. Of particular interest in this context is the role
of mutant p53, which is almost universally detected in metastatic
HGSOC cancers (Cancer Genome Atlas Research Network, 2011),
but can occasionally be found in the form of p53 signatures in
healthy patients with unclear clinical significance (Lee et al, 2007).
Thus, it cannot be excluded that the occurrence of mutated p53 is
coupled to additional, independent transformation stimuli that
provide a selective advantage during the process of transformation.
Several studies have investigated drug responses of different
patient-derived 3D models of HGSOC in short-term culture, but
conditions suitable for stable long-term cultivation and creation of
biobanks have remained elusive (Hill et al, 2018; Maru et al, 2019;
Phan et al, 2019). The recently reported generation of organoid
cultures from ovarian cancer (Kopper et al, 2019) demonstrated that
it is possible, in principle, to maintain the major properties of ovar-
ian cancer tissue in vitro. Notably, while providing a comprehensive
1 Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany
2 Department of Gynecology, Charité University Medicine, Campus Virchow-Klinikum, Berlin, Germany
3 BIH Genomics Core Unit, Charité University Medicine, Campus Virchow-Klinikum, Berlin, Germany
4 Department of Pathology, Charité University Medicine, Campus Charité, Berlin, Germany
5 Department of Gynecology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany
*Corresponding author. Tel: +49 3028 460400; E-mail: tfm@mpiib-berlin.mpg.de
**Corresponding author. Tel: +49 3045 0653504; E-mail: mirjana.kessler@charite.de
†Present address: Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité University Medicine, Berlin, Germany
ª 2020 The Authors. Published under the terms of the CC BY NC ND 4.0 license The EMBO Journal 39: e104013 | 2020 1 of 23
overview of the different histological subtypes and stages of the
disease, only two cases (five lines in total) from the reported cohort
involved samples from primary surgery, while the remainder were
pre-exposed to neoadjuvant chemotherapy. Interestingly, four out of
five primary HGSOC organoid lines exhibited slow growth, suggest-
ing suboptimal culture conditions. To date, it remains unclear how
the stem cell niche is altered in the native HGSOC tumor tissue
compared to healthy epithelium. Here, we define growth conditions
needed to achieve stable, long-term expansion of HGSOC organoids
from primary tumor deposits. We show that the niche composition
for stemness maintenance of cancer organoids requires low-Wnt
signaling and benefits from active BMP signaling, which is in
contrast to the paracrine environment that regulates epithelial
homeostasis in healthy FT organoids (Kessler et al, 2015).
In total, we have created 15 stable organoid lines from 13
primary deposits of advanced HGSOC patients, which match the
mutational and phenotypic profile of the parental tumor. In parallel,
we have generated FT organoid cultures from seven different
patients with simultaneous depletion of p53, PTEN, and RB (triple
shRNA knockdowns), leading to the disruption of major signaling
pathways that have been implicated in HGSOC development. Impor-
tantly, long-term growth of triple KD organoids could only be
sustained in medium adapted for HGSOC organoids. Comparative
gene expression analysis of cancer organoids and p53/PTEN/RB
triple KDs under different growth conditions revealed common key
regulatory changes in markers of stemness and differentiation. This
implies that signaling cues from the stem cell environment need to
change early during tumorigenesis to facilitate the growth of
mutated cells and are preserved in the advanced disease setting.
Thus, this study discovers important core principles in the develop-
ment of HGSOC, which have important implications for understand-
ing early carcinogenesis and disease progression.
Results
Establishment of HGSOC organoid culture
In order to define conditions for long-term in vitro propagation of
primary cancer organoids from solid HGSOC deposits, we utilized a
combinatorial screening approach, using samples obtained during
primary debulking surgery. To avoid potential contribution from
healthy fallopian tube or ovarian surface epithelium, only tumor
samples from peritoneum and omentum deposits were used. The
tissue was not pre-exposed to pharmacological agents, as all but one
HGSOC patient underwent radical surgery prior to chemotherapy, in
line with local clinical guidelines. Small pieces (1–3 cm) of
suspected tumor mass identified by the surgeon were transported to
the lab and subjected to cell isolation on the same day. 3D culture
was initiated by seeding the cell suspension in Matrigel and supple-
mentation with growth factors (for details see Methods and Proto-
cols). Overall, 15 organoid lines were successfully established from
13 out of 45 patients (~ 30% efficiency), which were classified
based on TNM and FIGO staging (Table EV1). The majority had
cancer deposits of > 2 cm that had invaded organs outside the
pelvis (T3c) and spread to retroperitoneal lymph nodes (N1), but
had not metastasized to more distant sites such as the liver or
spleen (M0) (Fig 1A). In order to generate a reference data set for
each organoid line, the parental tumor sample was divided into
three parts for (i) confirmation of the diagnosis by an experienced
pathologists using histological analysis of standard HGSOC biomark-
ers (Fig EV1A), (ii) isolation of DNA and RNA, and (iii) isolation of
cells for organoid culture (Fig 1B).
By testing media containing different combinations of growth
factors (Fig 1C), we identified conditions that support outgrowth
and long-term expansion (> 1 year) of cancer-derived organoids.
Normal FT organoid medium (FTM) (Table EV2) is supplemented
with ROCK and TGF-b receptor inhibitors, as well as Noggin, EGF,
FGF, RSPO1, and Wnt3a (Kessler et al, 2015; Kopper et al, 2019).
By contrast, HGSOC organoids did not grow in this medium but
required several alterations. The only paracrine growth factor that
proved indispensable was EGF (E). Most notably, unlike healthy
organoids from several different organs (intestinal, FT, gastric, liver,
etc.), which require exogenous Wnt activation, not a single organoid
line could be maintained in medium containing the Wnt signaling
agonist Wnt3a (W) (Fig 1C and Table EV3). Two lines did,
however, expand in the presence of the Wnt agonist R-spondin 1
(RSPO1, short R), suggesting that some cultures benefit from the
addition of RSPO1 (Fig 1C). In addition, sustained inhibition of BMP
signaling by Noggin (N) seems to be detrimental, as removal of
Noggin was a prerequisite for successful cultivation in 13/15
HGSOC samples, indicating fundamentally different roles of BMP
and Wnt signaling in the regulation of stemness in HGSOC
compared to normal tissue. Indeed, activation of Wnt pathway by
GSK3-b inhibitor CHIR99201 (CHIR), instead of addition of Wnt3a
agonist, also showed clear negative effect on organoid formation
and growth supporting conclusion that regulation of stemness
potential in HGSOC tissue has altered requirement for Wnt signal
(Fig EV1B). In summary, 11/15 cultures could be initiated and
expanded in medium containing only EGF, ROCK, and TGF-b inhibi-
tors, but without Noggin—thus allowing endogenous BMP signaling
(Table EV3). Five of these 11 samples benefited from the addition of
BMP2 for organoid formation, further amplifying BMP signaling (B).
As this patient-dependent effect of BMP2 addition was always
neutral or positive, BMP2 was subsequently included in the stan-
dard medium composition. Therefore, the combination of EGF and
BMP2, together with other standard components of organoid
medium, i.e., ROCK inhibitor, TGF-b inhibitor, B27, N2, and nicoti-
namide (consistent with Kopper et al, 2019), was termed ovarian
cancer minimal medium (OCM) (Table EV3).
Successfully established long-term HGSOC organoid cultures
were passaged at a ratio of 1:2 to 1:3 every 10–20 days for at least
5 months prior to cryopreservation. Six lines were kept in culture
for > 1 year (Table EV3). Thawed cancer organoids could routinely
be expanded to a multi-well screening format and are thus suited for
generating live biobanks of HGSOC organoids to explore individual
therapeutic options in vitro. Multiple cycles of thawing and freezing
were tested on seven different lines without noticeable changes in
morphology or expansion potential.
Immunofluorescence labeling confirmed that the organoids
exhibit all hallmarks of an HGSOC phenotype, including disorga-
nized tissue architecture and loss of polarity (as marked by the
absence of a central cavity), an epithelial secretory identity of all
cells (strong EpCAM and PAX8 expression), and pleomorphic nuclei
(Fig 1D). HE staining further confirmed their morphological similar-
ity to the matching tissue samples (Fig 1E). Next, we tested the
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in vitro drug response to carboplatin, the major first-line chemother-
apeutic agent for HGSOC. As expected, organoids underwent cell
death in a concentration-dependent manner, with prominent dif-
ferences between organoids from different donors suggesting indi-
vidual variation in drug response among patients (Figs 1F and
EV1C).
HGSOC organoids match tumor tissue in mutational profile and
expression of biomarkers
To test whether patient-derived organoid cultures correspond to the
individual mutational profile of the parental tumor, we performed
targeted sequencing for 121 candidate genes that were selected on
the basis of previously published studies of ovarian cancer genomic
profiles (Appendix Table S1; Cancer Genome Atlas Research
Network, 2011, Norquist et al, 2018). Mutational analysis of 10
paired tumor fragments and organoids from nine different patients
revealed that despite the long-term expansion in vitro (DNA samples
were collected after 4–10 months in culture, see Table EV3), they
retained a high level of similarity, even including allelic frequency,
when compared to the tissue that was immediately frozen on the
day of surgery (Fig 2A and Table EV4). TP53 mutations were
detected in the vast majority of samples (9/10), in agreement with
the almost universal occurrence of mutated p53 in HGSOC patients
(Cancer Genome Atlas Research Network, 2011). All of the TP53
mutations in the organoid cultures were homozygous (> 0.9 allele
frequency), yet diverse with respect to mutation type (missense,
nonsense, frame-shift, or splice variant mutations). In addition to
somatic mutations with proven tumorigenic potential, a number of
known variant alleles were identified, including ROCK2
(c.1292C>A), KIT (c.1621A>C), MLH1 (c.655A>G), and MSH6
(c.472C>T) which could potentially influence the malignant pheno-
type (Kalender et al, 2010; Nakamura et al, 2014; Brahmi et al,
2015). Apart from TP53, MLH1, and MSH6, we also found point
mutations in other genes with functions in DNA repair and chromo-
some stability, including ATM (c.4534G>A), ATR (c.1517A>G),
BRIP1 (c.254T>A), and FANCA (c.1238G>T). Interestingly, while no
classic germline or somatic BRCA1/2 mutations were detected apart
from three polymorphisms that are weakly associated with ovarian
cancer (c.4900A>G, c.3113A>G, c.2612C>T), analysis of protein
lysates revealed a significant reduction compared to healthy FT
organoids in three of eight cases (OC4, OC2, and OC3; Appendix Fig
S1A and Table S2). This strongly suggests the existence of epige-
netic or post-transcriptional mechanisms of BRCA1 inactivation in
these cases. Altogether, 7/9 patients had mutations in one or more
DNA repair gene, in congruence with the fact that HGSOC is a
cancer characterized by a particularly high incidence of genomic
instability. Given our finding that HGSOC organoids could not be
maintained in the presence of Wnt, we noted with interest that three
missense mutations in Wnt pathway genes (Fzd9, LRP5, and
TCF7L2) were identified in three different patients (Fig 2A), which
could impair signal transduction and thus provide further evidence
that changes in this pathway play an important role in ovarian
carcinogenesis. Complementary to the sequencing data, WB and IF
staining were performed to examine the mutational status and
subcellular localization of p53 in the organoids
(Appendix Table S2). While the nonsense mutation in OC11 as well
as the splice variant and frame-shift mutations in OC4 and OC7,
respectively, result in loss of p53 (Fig 2B and Appendix Table S2),
the missense mutations in OC9 (p.R273H), OC10 (p.R175H), OC1
(p.V25F), and OC6 (p.V173M) result in a gain-of-function and
nuclear accumulation phenotype with R273H and R175H being two
of the most common mutations in ovarian cancer (Zhang et al,
2016; Fig 2C and Appendix Fig S1B).
To more thoroughly evaluate parallels between tissue and orga-
noid cultures, a global gene expression analysis was performed from
eight different tumor/organoid pairs as well as three healthy FT
tissue/organoid pairs and two FT organoids derived from cancer
patients (also classified as normal healthy tissue). The generation of
a multi-dimensional-scaling plot (MDS) revealed that the distance
between OC and FT organoids is smaller than between correspond-
ing tissues, likely due to the greater complexity of tissue samples,
which contain mesenchymal and endothelial components (Fig 2D).
Still, despite the tissue heterogeneity, the respective OC organoids
express very similar levels of the main cancer markers, like
CDKN2A (p16), Muc16, and EpCAM, when compared to the
parental sample (Fig 2E). Moreover, correlation analysis of FT and
OC organoids (Appendix Fig S1C) shows that FT samples form a
homogenous cluster and show less variability in gene expression
between each other than OC organoids, which instead reflect the
phenotypic diversity of ovarian tumors.
A thorough analysis of gene expression revealed that numerous
hallmark genes known to be de-regulated in HGSOC are differen-
tially expressed between OC and normal FT samples, not only in the
tissue but also in the organoids (Fig 2F). This includes significant
up-regulation of the cell cycle regulators CDKN2A and Cyclin E1
(CCNE1) and the transcription factor FOXM1, as well as downregu-
lation of differentiation markers like PGR and OVGP1.
The strong up-regulation of Cyclin E1 was validated by Western
blot analysis in five out of eight samples tested (Appendix Fig S1D
◀ Figure 1. Establishment of patient-derived organoids from solid HGSOC deposits.A Summary of cancer patient data with TNM and FIGO classifications showing advanced stage of disease at the time of surgery.
B Graphic representation of the standard experimental procedure for tumor patient material. Samples were obtained at the time of primary debulking surgery from the
high purity tumor deposits in peritoneum/omentum.
C In vitro niche dependency of HGSOC tumor cells. Phase-contrast pictures illustrate that isolated ovarian cancer cells rely on EGF supplementation for growth, while
they do not grow at all in Wnt3a-supplemented medium. Also, inhibition of BMP signaling through Noggin has strong negative effect on the initial growth. Scale bar:
500 lm. E—EGF, F—FGF10, N—Noggin, R—R-spondin1, B—Basic medium, P—Passage.
D Cancer organoids express HGSOC markers Pax8 and EpCAM and have lost the cystic phenotype suggesting complete breakdown of epithelial polarity as seen on
confocal images from two representative organoid lines. Scale bar: 20 lm.
E HE staining of organoids and respective tissue confirms high similarity in cellular structure and tissue organization. Scale bar: 100 lm.
F HGSOC organoids show differential response to carboplatin treatment, confirming patient-specific sensitivity of the cultures. Cell viability assay was performed after
5 days of treatment with different concentrations of carboplatin on mature organoids from three different donors. Data represent mean  SD of technical triplicates.
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and Table S2), while the level of RB protein itself, which is phos-
phorylated by Cyclin E1 to promote G1/S progression, was not
changed (Appendix Table S2). This indicates potential RB pathway
disruption by increased Cyclin E1 levels. Amplification of CCNE1
gene is common in HGSOC (~ 20–30% of cases), but increased
levels could also be a result of alternative signaling perturbations.
Together, these results demonstrate that the patient-derived OC
organoid lines are valid in vitro models of the parental HGSOC
tumors, resembling not only the tissue architecture but also the
mutational profile and overall gene expression.
Stable triple knockdown of p53, PTEN, and RB in FT organoids
In the next step, we wanted to analyze at which stage of disease
development the observed changes in niche factor requirements
occur. This is a question of particular importance in HGSOC, where
transformation appears to occur in the FT but cancers are very
rarely detected at this site. To mimic the cellular events, like muta-
tion of p53 and loss of PTEN, which characterize the early stages of
malignant transformation, we used organoids from healthy FT
donor epithelium. In contrast to previous in vitro tumorigenesis
models, which were based on the transformation of immortalized
primary FT monolayers (Jazaeri et al, 2011; Nakamura et al, 2018),
organoids are genomically unaltered and have preserved epithelial
polarity and integrity, thus ensuring mucosal homeostasis.
In order to model HGSOC development, shRNAs against p53,
PTEN, and RB—major known tumor drivers of the disease—were
introduced into healthy human FT epithelial cells from donor tissues
obtained during surgeries for benign gynecological conditions. The
shRNAs were delivered sequentially by retro- and lentiviral vectors
into epithelial cells grown in 2D culture, selected by FACS (shPTEN-
mCherry, shRB–GFP), and subsequently transferred to Matrigel to
initiate organoid formation (Figs 3A and EV2A). Among the double-
positive mCherry/GFP population (shPTEN, shRB), p53-depleted
organoids were selected with puromycin. Successful knockdown of
all three target genes was confirmed on RNA as well as protein level
(Fig 3B). In total, seven triple knockdown (KD) cultures were
successfully generated from different FT donor tissue confirming
robustness of the methodology (Fig EV2D). In congruence with the
downregulation of RB and PTEN protein, functional analysis of triple
KD organoids revealed an increase in the expression of Cyclin E1
(Fig 3C) and elevated levels of activated phosphorylated Akt (pAkt),
respectively (Fig EV2B). Functional disruption of p53 pathway was
confirmed by resistance of organoids to the MDM2 inhibitor Nutlin-
3A, which triggers apoptosis in p53 WT cells (Fig EV2C).
We next compared phenotypes of KD and WT organoids by
confocal microscopy. We observed loss of cell shape and misalign-
ment of the nuclei, indicative of changes in the maintenance of
apicobasal polarity—although the organization of the monolayer
remained intact and the lumen was preserved with a cystic growth
of the organoids. Triple KD cells also showed a stronger signal for
the DNA damage marker yH2AX, indicating an increased frequency
of DNA double-strand breaks and thus suggesting genomic instabil-
ity (Fig 3D). Notably, KD organoids had enlarged and polymorphic
nuclei, which is one of the prominent morphological characteristics
of HGSOC cells (Fig 3D). While all these phenotypic changes
suggest that the knockdown of p53, PTEN, and RB in FT organoids
is pro-carcinogenic, none is sufficient as bona fide evidence of
malignancy. Indeed, KD cells remained competent to undergo dif-
ferentiation into ciliated cells, which are thought to be the termi-
nally differentiated cells of the FT (Fig 3E).
Rescue of KD organoid lines in ovarian cancer medium
Despite an initial growth advantage until the first passage after seed-
ing, KD organoids cannot be maintained in long-term culture and
undergo growth arrest after 4–8 passages, as shown by the growth
curve in comparison with WT and vector control (Fig 4A and
Appendix Fig S2A). While individual differences among different
donor cultures were observed, the premature growth arrest of KD
organoids was confirmed in 7/7 cases (Fig EV2D). This suggests
that the KD organoids may undergo similar changes in stemness
regulation as those observed in the HGSOC organoids.
Indeed, growing the organoids in ovarian cancer medium
improved organoid formation efficiency and enabled long-term
growth (Fig 4B). Importantly, long-term growth could only be
rescued if OCM was added at passage 0/1, suggesting that inade-
quate niche conditions lead to irreversible loss of stemness. Phase-
contrast images (Appendix Fig S2B) confirm that while individual
organoids grow to a similar size, organoid numbers are lower at
each passage in FTM, finally resulting in premature growth arrest.
Western blot analysis of cH2AX and cleaved caspase-3, as well as
PARP1, indicated that the growth-suppressive effect of Wnt3a did
not result from direct cytotoxicity, as DNA damage and apoptosis
were not reduced when organoids were grown in OCM (Fig 4C and
Appendix Fig S2C). Single p53 or double p53/PTEN KD on the other
◀ Figure 2. HGSOC organoids match tumor tissue in mutational profile and gene expression biomarkers.A Overview of mutations found in organoid cultures and matching tumor tissue obtained by targeted sequencing of 121 HGSOC-related genes confirms almost
identical profile between parental tissue and in vitro long-term organoid culture. Color code indicates type of mutations which were detected.
B Representative Western blot showing loss or overexpression of p53 in individual organoid lines.
C Strong nuclear p53 signal in immunostainings of HGSOC organoids is indicative of a gain-of-function TP53 mutation. Scale bars: 100 lm (tissue) and 50 lm
(organoid).
D Multi-dimensional scaling (MDS) plot based on the gene expression profiles (microarrays) of three healthy FT and eight tumor tissue samples and their respective
organoid cultures shows four clusters: normal FT tissue, normal FT organoids, cancer organoids, and cancer tissue.
E Box plots depicting overall constant level in normalized expression of major HGSOC marker genes between organoids and parental tissue. Data represent the median,
quartiles, maximum, and minimum of the normalized expression from eight different donors.
F Heat map of differentially expressed genes between cancer and healthy tissue/organoids reveals up-regulation of several HGSOC biomarkers and reduction in FT
differentiation markers in the cancer samples. Differential expression determined by single-color microarray for eight different patient samples was significant for all
genes with P < 0.05 except for OVGP1 and TOP2A in organoids.
Source data are available online for this figure.
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hand did not exhibit increased cH2AX levels, irrespective of the
medium used, indicating that the enhanced DNA damage observed
in triple KDs is the result of RB depletion.
In order to discover factors induced by culture in OCM that
contribute to maintenance of stemness and longevity of the triple
KD and HGSOC organoids, we performed global gene expression
analysis. As expected, OCM medium devoid of Wnt3a and RSPO1
led to a reduction in the expression of Wnt target genes in both,
triple KD and WT, organoids (Appendix Fig S2D). The microarray
data also reveal that despite cell growth arrest of the KD organoids
in FTM, they continue to show elevated expression of classical
HGSOC markers, including FOXM1, TOP2A, CDKN2A, and WT1,
albeit at lower levels than when grown in OCM (Fig 4D). This
finding proves that knockdown of key tumor suppressor genes is
sufficient to induce a degree of cellular transformation toward a
cancer phenotype and supports the view that the FT epithelium is
the tissue of origin of HGSOC.
However, a clear increase in the expression of genes related to
stemness (CD133, MYCN, and SOX2) and a decrease in genes related
to differentiation (PGR, OVGP1, and FOXJ1) were found in KD orga-
noids grown in OCM vs. FTM (Fig 4E). While PGR and ESR1 are dif-
ferentiation markers connected to hormone signaling, FOXJ1 is the
major transcription factor required for ciliogenesis and thus develop-
ment of multiciliated cells, presumed to be the terminally differenti-
ated cell type in the FT mucosa. The downregulation of FOXJ1
compared to the vector control was validated by qPCR for organoids
from two patients (Fig 4F). In addition, quantification of immunola-
beling against detyrosinated tubulin (Fig 4G) in three independent
organoid lines confirmed a lack of multiciliated cells in the triple KD
organoids grown in OCM, but not in FTM. Since FT mucosa renewal
is driven by the differentiation of bipotent progenitors (Kessler et al,
2015; Ghosh et al, 2017), the absence of ciliated cells is suggestive of
a shift toward the secretory phenotype. Notably, an outgrowth of
secretory cells is thought to be a critical step in the development of
HGSOC from FT epithelium. Our findings indicate that this process
can be triggered in vitro by p53/PTEN/RB depletion, provided that
canonical Wnt pathway activation is reduced.
Wnt-free medium supports stemness of HGSOC and KD organoids
Next, we wanted to confirm independently that Wnt-free medium
increases stemness of KD organoids. FACS analysis of the bona fide
OC stem cell marker CD133 (Kryczek et al, 2012), which is
expressed on the cell surface, revealed that the number of positive
cells in triple KD organoids increased when cultured in OCM vs.
FTM (Fig 5A and Appendix Fig S3A). In vector ctrl and WT cells, by
contrast, the number of CD133+ cells was lower in OCM, consistent
with FTM providing more optimal conditions for the preservation of
stemness in healthy epithelial cells. Loss of stemness coincides with
a reduction in growth potential as quantified by a luciferase-based
assay determining the number of live cells after two passages of
parallel cultivation in the different media (Fig 5B). This confirms
that the presence of Wnt agonists in the environment hampers the
growth of p53/PTEN/RB KD organoids by repressing stemness—
indicative of a substantial change in stemness regulation.
To substantiate these results, we analyzed the direct effect of
Wnt3a/RSPO1 supplementation on patient-derived HGSOC organoid
growth and CD133 surface expression. Differential treatment of
cancer organoids over 2 passages clearly showed that addition of
these Wnt agonists to OCM resulted in a highly significant
(P < 0.001) inhibition of organoid growth, an effect confirmed for
all five OC organoid lines tested (Fig 5C). Interestingly, the inhibi-
tory effect of Noggin on already established cultures was mild, but
significant, confirming that BMP pathway activity is beneficial for
growth but not as essential as for initial organoid formation.
However, addition of Noggin to mature organoid lines had no effect
on the number of CD133+ cells, while the presence of Wnt3a/
RSPO1 reduced CD133+ numbers significantly (Fig 5D and
Appendix Fig S3B), suggesting that the negative influence of canoni-
cal Wnt pathway activation on HGSOC organoid growth is poten-
tially connected to the regulation of CD133 surface expression.
As Wnt3a supplementation relies on the addition of conditioned
medium from a Wnt-producing cell line, we next wanted to confirm
that its effect was specific to the presence of Wnt. Indeed, Wnt-
conditioned medium strongly upregulated the established Wnt
target gene AXIN2 (Appendix Fig S3C). In addition, medium condi-
tioned by the parental cell line without the Wnt-producing vector
(CM) did not negatively affect organoid growth (Fig 5E).
Overall, it can be concluded that the presence of Wnt ligands,
which induce a signature of canonical Wnt target gene expression in
KD and HGSOC organoids, results in a striking decrease in stemness
and growth capacity in these cultures.
MYCN and Wnt inhibitors are upregulated in HGSOC and
KD FT organoids
The data from HGSOC organoids provide strong evidence that the
mechanisms by which growth of cancer organoid stem cells is
◀ Figure 3. Stable triple knockdowns of tumor suppressors p53, PTEN, and RB in healthy FT organoids.A Experimental approach for genetic manipulation of FT epithelial cells (FTECs). FTECs were sequentially transduced in 2D culture with replication-deficient viruses
containing specific shRNAs and different selection markers. After sorting, cells were seeded in Matrigel for organoid formation. Scale bars: 2 cm (tissue), 200 lm (2D
culture), and 500 lm (3D culture).
B Confirmation of robust knockdowns of p53, PTEN, and RB in FT organoids on RNA and protein level. Relative mRNA levels were normalized to the WT mRNA level and
are given as the mean  SEM from three different donors. A representative Western blot from one donor is depicted. RNA and protein samples were taken at passage
1 or 2 of each organoid line. KD—knockdown, Vec Ctrl—vector control, WT—wild type.
C Cyclin E1 overexpression as a downstream effect of RB knockdown was confirmed by Western blot analysis.
D Confocal images of triple KD organoids reveal increased DNA damage (yH2AX, marked by asterisks), atypic nuclei (DRAQ5), and loss of apicobasal polarity. Scale bar:
20 lm.
E Presence of ciliated cells (arrowheads), as revealed by immunostaining against detyrosinated Tubulin (dtyrTub) in triple KD organoids, proves capacity for terminal
differentiation. Scale bar: 50 lm.
Source data are available online for this figure.
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maintained are altered from those in the healthy epithelium, and
our experiments with KD organoids further show that depletion of
only three tumor driver genes can recapitulate this effect. To get a
better insight into putative candidate genes that could contribute to
the maintenance of stemness in cancer organoids, we compared
microarray data of healthy FT epithelium and HGSOC tissue as well
as patient-derived cancer and KD organoids grown in the ovarian
cancer minimal medium (OCM) vs. the fallopian tube medium
(FTM) (Fig 6A). The proto-oncogene MYCN was uniformly upregu-
lated in cancer tissue, as well as triple KD organoids cultured in
OCM, suggesting that it may play a role in driving stemness and
cancer growth in HGSOC. qPCR confirmed MYCN expression to be
significantly higher in cancer organoids compared to FT organoids
(Fig 6B, left panel). In addition, the expression levels of MYCN rela-
tive to GAPDH were validated by qPCR in three independent biologi-
cal replicates of triple KD organoids cultured in OCM vs. FTM
(Fig 6B, right panel).
In line with our finding that reduced canonical Wnt signaling
supports the growth of cancer organoids, the gene expression data
revealed enhanced expression of the Wnt inhibitors KREMEN2 and
DKK3 (Mao et al, 2002; Yue et al, 2008) in both triple KD and OC
organoids (Fig 6A). While KREMEN2 regulation appears to be
driven by changes in the genetic background, DKK3 expression
seems to be induced by Wnt-free medium. Therefore, it appears that
the altered paracrine signaling environment further promotes inhibi-
tion of canonical Wnt signaling. Interestingly, downregulation of
p53/PTEN/RB in FT organoids caused a decrease in Wnt target gene
expression even in the presence of Wnt3a and RSPO1 (Fig 6C),
while culture in Wnt-free medium leads to a further strong reduc-
tion in LEF1 and TCF transcripts down to the detection limit of the
microarray (Appendix Table S3). The expression of Wnt inhibitors
and the reduced Wnt signaling induced by tumor suppressor KD are
in agreement with our hypothesis that Wnt pathway suppression is
required for HGSOC growth, which can be achieved by different
molecular mechanisms—cell autonomous and/or by changes in the
niche environment. Interestingly, HGSOC organoids expressed
increased levels of differentiation markers when exposed to Wnt3a/
RSPO1. In line with the microarray results and data from the triple
KD organoids, qPCR confirmed increased expression of the
ciliogenesis factor FOXJ1 in cancer organoids cultured in the pres-
ence of Wnt3a/RSPO1 (Fig 6D). Based on this, we postulate a two-
step process of HGSOC development in which changes in the niche
environment are a necessary step that drives dedifferentiation and
maintains stemness in cells bearing tumorigenic mutations.
Discussion
Our understanding of the cellular mechanisms that underlie the
development of HGSOC in the FT and its spread to the ovaries and
beyond remains rudimentary and represents a major obstacle to
advances in diagnosis and therapy. Although some properties of
cancer stem cells in HGSOC have been described (McLean et al,
2011; Choi et al, 2015; Lupia & Cavallaro, 2017), there is no knowl-
edge about the intrinsic mechanisms that drive tumor growth and
mediate recurrent disease. As patients frequently receive neoadju-
vant chemotherapy prior to debulking surgery, such tumor samples
are likely to already show secondary biological alterations. This
study thus provides systematic insight into the biology of HGSOC
organoids derived directly from primary debulking surgery samples,
which reflect the biology of the initial cancer tissue.
In contrast to the healthy FT epithelium (Kessler et al, 2015), we
find that HGSOC cancer organoids require a low-Wnt signaling envi-
ronment but an active BMP signaling axis. Wnt independence was
previously observed in other cancers such as pancreas and colon
(Fujii et al, 2016; Seino et al, 2018) and positively correlates with
the clinical progression. However, in contrast to organoids from
other cancers, e.g., metastatic pancreatic cancer, which do not
require Wnt but do grow in Wnt/RSPO/Noggin medium, exogenous
supplementation of Wnt3a actually prevented formation and growth
of all HGSOC cancer organoids. Recently, Kopper et al (2019) also
reported the use of Wnt-free medium for the generation of HGSOC
organoids but attributed negative effect of Wnt to the potential
contaminating presence of serum. Here, we clearly show that lack
of exogenous Wnt signal activation is in fact a requirement for
maintaining stemness and preventing differentiation in HGSOC
organoids and that pro-cancerous mutations by themselves are
therefore likely not sufficient to drive transformation of healthy
◀ Figure 4. Triple KD organoids show improved growth in ovarian cancer medium.A In long-term 3D culture, triple KD organoids show loss of growth capacity and premature growth arrest compared to the controls as indicated by the representative
growth curves of FT234. Scale bar: 500 lm.
B Growth curves and phase-contrast images of triple KD organoids grown in OCM compared to FTM reveal successful rescue of long-term growth capacity. Scale bar:
500 lm.
C Levels of DNA damage (yH2AX) and apoptosis (cleaved caspase-3, PARP1) do not differ among the different media as shown by representative Western blots
comparing triple KD organoids and their controls.
D Triple KD (p53/PTEN/RB) organoids are characterized by a HGSOC gene expression signature as revealed by microarray analysis comparing WT and KD organoids
grown in either OCM or FTM. Differential expression determined by dual-color microarray for two biological replicates was significant for all genes with P < 0.00005.
E Differential expression of stemness- and differentiation-related genes of triple KD organoids grown in OCM vs. FTM. Fold changes were derived from microarray data
and indicate an increase in stemness (CD133, SOX2, MYCN) and a drop in differentiation (OVGP1, PGR, FOXJ1) under OCM conditions. Differential expression
determined by dual-color microarray for two biological replicates was significant for all genes with P < 0.05.
F FOXJ1 expression determined by qPCR was significantly diminished in triple KD organoids grown in OCM compared to FTM, suggesting a decrease in differentiation
capacity. Data represent the mean  SEM from technical triplicates for two independent knockdown cultures.
G Proportion of ciliated cells (detyrosinated tubulin; dtyrTub) is significantly reduced in KD organoids under OCM growth conditions, confirming inhibition of
differentiation as illustrated by confocal images (Scale bar: 50 lm). The quantification plot depicts the mean  SEM from three independent biological replicates,
based on quantification of the average number of ciliated cells per counted nuclei. 1,000 cells were counted per individual experiment. *P < 0.05, two-sided Student’s
t-test.
Source data are available online for this figure.
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epithelium. Importantly, activation of Wnt pathway through action
of the GSK3-b inhibitor CHIR also inhibits organoid growth, which
independently confirms functional relationship between low-Wnt
signal and maintenance of HGSOC growth potential in vitro. This
provides mechanistic experimental validation of findings from a
large GWAS study that identified genomic variants of the Wnt path-
ways agonist Wnt4 and RSPO1 loci to be associated with increased
susceptibility for epithelial ovarian cancer development, and
showed decreased expression of Wnt4 in the cancer tissue (Kuchen-
baecker et al, 2015). Although we used Wnt3a in our experiments,
the extensive functional redundancy among the Wnt family
members suggests that Wnt4 stimulation would have a similar
effect.
Notably, we also clearly demonstrate that active BMP signaling is
an important factor for the formation of cancer organoids (13/15
lines could only be initiated without Noggin in the medium), and
for long-term growth. As Noggin was a standard medium compo-
nent in previous studies (Hill et al, 2018; Kopper et al, 2019), this
potentially explains the reported difficulties with long-term mainte-
nance. Thus, it is tempting to speculate that the overall environment
in the FT epithelium (with presumably high-Wnt signaling)
represses cancer outgrowth and promotes escape of (pre-)malignant
cells to more distant sites, like the surface of the ovaries and peri-
toneum. Interestingly, even the formation of the two organoid
cultures that benefited from the presence of RSPO1 (Fig 1) could be
efficiently prevented by addition of Wnt3a and Noggin, suggesting
high sensitivity of the HGSOC organoids to elevated Wnt signaling.
Nevertheless, these cases show that the heterogeneity of this disease
warrants routine testing of two different media during the establish-
ment of fresh cultures: OCM and OCM + RSPO1 and FGF.
Our analysis of HGSOC and KD organoids clearly demonstrates
that a high-Wnt environment leads to the downregulation of stem-
ness genes and the up-regulation of differentiation genes. Mouse
lineage tracing data previously showed that active Wnt signaling is
required for both renewal of Pax8 secretory cells and their differenti-
ation to ciliated cells (Ghosh et al, 2017). Our data strongly suggest
that the regulation of these processes becomes separated during
carcinogenesis. While Wnt stimulation still induces differentiation
and ciliogenesis in cancer organoids, it inhibits their longevity and
expansion capacity. The same effect is observed in triple KD orga-
noids, indicating that depletion of key tumor driver proteins is suffi-
cient to induce these alterations in stem cell regulation. Yet, despite
the change in growth requirements, the prominent occurrence of
nuclear atypia, increase in DNA damage, and changes in epithelial
organization, triple KD organoids maintained key elements of epithe-
lial polarity. Therefore, it appears they have not completed the
process of transformation and that additional changes are needed for
malignancy to develop. This is also in line with the observation that
growth rescue in OCM medium was incomplete. Unlike the stable
long-term expansion of HGSOC organoids, which were routinely
cultured for over 1 year without changes in growth dynamics, the
lifespan of KD organoids in OCM was limited to 7–8 months.
Our data illustrate the critical importance of the model system
when studying processes of cell transformation in vitro. Several
previous studies on the putative role of the FT as the tissue of origin
of HGSOC showed the transformation potential of human FT epithe-
lial cells in 2D cell culture by overexpression of different oncogenes
(h-RAS, c-MYC) followed by xenograft transplantation (Jazaeri et al,
2011; Karst et al, 2011). We show that robust regulatory mecha-
nisms in the intact epithelium prevent the breakdown of the epithe-
lial organization despite functional inactivation of the key HGSOC
drivers p53, PTEN, and RB. Breakdown of apicobasal polarity is an
important step in the emergence of many cancers, as it precedes
EMT and thus facilitates cancer progression (Huber et al, 2005;
Ozdamar et al, 2005). While our microarray data revealed important
similarities in gene expression profile between KD FT organoids and
mature cancer organoids, further studies are needed to elucidate the
exact mechanism of cancer stem cell maintenance in HGSOC.
MYCN, which in the absence of Wnt was ubiquitously upregulated
in all HGSOC and KD FT organoids in our study, was previously
implicated as a driver of stemness in aggressive glioblastoma (Yang
et al, 2017b). The high degree of consistency in MYCN regulation in
KD FT and HGSOC organoids from independent donor samples
warrants further studies to investigate its potential role as a stem-
ness marker in HGSOC. Also, while we show that surface expression
of CD133 correlates with in vitro growth capacity of HGSOC orga-
noids, the exact functional relationship between stemness regulation
in the organoid culture and other previously described ovarian
cancer stem cell markers CD117, ALDH1 and CD24 (Gao et al, 2010;
Kryczek et al, 2012; Yang et al, 2017a) is yet to be tested.
Our data strongly suggest the existence of signaling cross-talk
between stemness maintenance in FT epithelium and the major
drivers of cellular transformation in HGSOC—p53, PTEN, and RB.
Although our KD FT organoids modeled conditions where p53 is
depleted, the patient-derived HGSOC lines included both loss-of-
function p53 mutations and frequent gain-of-function alleles. No
◀ Figure 5. Wnt depletion supports preservation of stemness in HGSOC organoids.A The proportion of CD133+ cells was determined by FACS analysis after growing triple KD and control cells in FTM vs. OCM for two passages. The graph is
representative of two biological replicates.
B Growth capacity increases when KD organoids are grown in OCM medium as shown by difference in total viable cell number (representative graph of three
independent experiments). The luminescent cell viability assay was performed in triplicate, and the bar plot depicts the mean  SEM. *P < 0.05, two-sided Student’s
t-test; KD—knockdown, Vec Ctrl—vector control, WT—wild type.
C Phase-contrast images of cancer organoids which entered growth arrest upon treatment with Wnt agonists (Wnt3a/RSPO1) over two passages (Scale bar: 500 lm).
Differences in cell number were confirmed by the respective cell viability assays (performed in technical triplicates). Data represent the mean  SEM for five different
OC organoid lines (n = 5). ***P < 0.001, two-sided Student’s t-test.
D The number of CD133+ cells determined by FACS for OC7 and OC4 organoids grown in different media with or without Wnt3a/RSPO1 and with or without Noggin
over two passages confirms a sharp drop in stemness in the presence of Wnt agonists.
E Addition of conditioned medium collected from the parental Wnt3a cell line did not suppress growth of cancer organoids, proving that the growth inhibitory effect is
due to the presence of Wnt agonists. The bar plot represents the mean  SEM of triplicates performed with a luminescent cell viability assay. *P < 0.05,
***P < 0.001, two-sided Student’s t-test.
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difference in growth factor requirements was detected in relation to
the type of p53 mutation.
The stability of patient-derived HGSOC organoid lines cultured
using our method makes it potentially suitable for translational
biomedical research. Preliminary tests with carboplatin showed
individual differences in drug response of organoids from different
patients. However, to define to which extent organoids are predic-
tive of in vivo patient responses, more comprehensive in vitro drug
testing studies in correlation with long-term clinical outcome are
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Figure 6. Unifying induction of MYCN and Wnt inhibitors in HGSOC and KD samples.
A Comparative analysis of microarray data revealed consistent up-regulation of MYCN and the canonical Wnt inhibitors KREMEN2 and DKK3 as well as down-
regulation of differentiation marker FOXJ1, AR, and PGR in HGSOC cancer organoids as well as triple KD FT organoids. Differential expression was determined either
by single-color microarray for the cancer samples (eight replicates) or by dual-color microarray for the knockdowns (two replicates) and is significant for all genes
with P < 0.05.
B Transcriptional induction of MYCN is confirmed by qPCR for three patients between cancer organoids and normal FT organoids as well as triple KD organoids grown
in OCM vs. FTM conditions. Depicted is the mean  SEM of the normalized MYCN mRNA expression level of three biological replicates (n = 3). **P < 0.01,
***P < 0.001, two-sided Student’s t-test.
C Microarray data revealed that the expression levels of Wnt target genes are downregulated in triple KD compared to WT control FT organoids. Differential expression
determined by dual-color microarray for two biological replicates was significant for all genes with P ≤ 0.005.
D FOXJ1 expression was upregulated in HGSOC organoids in FTM compared to OCM as shown by qPCR analysis of three different patient samples. Data represent the
mean  SEM of technical triplicates.
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therapy, which is of critical importance for the development of new
treatment approaches, paired organoid cultures could be generated
from primary disease and after recurrence in the same patients.
It is possible that including other cell types in the organoid
model, such as stromal and immune cells, could further advance its
capacity to generate data which are predictive of clinical responses
in patients (Neal et al, 2018).
Overall, this study provides important insight into fundamental
biological processes of HGSOC development. We show that func-
tional inactivation of key tumor drivers fails to induce a direct
growth advantage of the altered cells in the absence of
appropriate changes in the stem cell niche environment. The exis-
tence of such a two-component mechanism opens up important
new questions for understanding the etiology of HGSOC—in
particular which cellular and physiological mechanisms in the
tissue surrounding the FT epithelium are responsible for the criti-
cal changes in paracrine signaling that favor the outgrowth of
mutated cells. In this context, the regulatory role of the neighbor-
ing ovary could further be of pivotal relevance, particularly in
light of epidemiological data showing a strong correlation between
inflammatory processes associated with ovulation and the risk for
HGSOC development.
Materials and Methods
Reagents and Tools table




HEK-293 cells (Homo sapiens) ATCC CRL-11268
L cells ATCC CRL-2648
L Wnt-3a ATCC
Willert et al (2003)
CRL-2647
293T HA Rspo1-Fc R&D
Farin et al (2012)
3710-001-01





pLVTHM-GFP-shLuciferase This study Appendix Table S4
pLVTHM-mCherry-shLuciferase This study Appendix Table S4
pLVTHM-mCherry-shPTEN This study Appendix Table S4
pLVTHM-GFP-shRB This study Appendix Table S4
pSUPER.retro Addgene 3926
pSUPER.retro.p53 Alexander Löwer
(Brummelkamp et al, 2002)
Appendix Table S4
retroviral packaging plasmid Alexander Löwer
(Brummelkamp et al, 2002)
retroviral envelope plasmid Alexander Löwer
(Brummelkamp et al, 2002)
Antibodies
Rabbit anti-BRCA1, WB (1:200) Santa Cruz sc-642
Mouse anti-cyclin E1 (HE12), WB (1:1,000) Cell Signaling 4129
Rabbit anti-cleaved caspase-3 (Asp175), WB
(1:1,000)
Cell Signaling 9661
Rabbit anti-detyrosinated a-tubulin, IHC
(1:100)
Abcam ab48389
Mouse anti-E-Cadherin, IHC (1:100) BD Biosciences 610181
Mouse anti-EpCAM (VU1D9), IHC (1:100) Cell signaling 2929S
Mouse anti-EpCAM (VU1D9), IHC (1:100) Thermo Scientific MA1-10195
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Reagents and Tools table (continued)
Reagent/Resource Reference or source
Identifier or catalog
number
Mouse anti-p16 (16P04), IHC (1:600) NeoMarkers
Mouse anti-p53 (1C12), IHC (1:2,000) Cell Signaling 2524
Mouse anti-p53 (DO-1), WB (1:500) Santa Cruz sc-126
Mouse anti-p53 (DO-7), (1:50) Dako M7001
Mouse anti-PARP, WB (1:2,000) Cell Signaling 9542
Rabbit anti-Pax8, IHC (1:50) Proteintech 10336-1-AP
Mouse anti-Pax8 (MRQ-50), IHC (1:100) Sigma 363M-1
Rabbit anti-phospho cH2AX (Ser139), WB
(1:1,000), IHC (1:400)
Cell signaling 9718
Rabbit anti-PTEN, WB (1:1,000) Cell Signaling 9552
Mouse anti-Rb (4H1), WB (1:2,000) Cell Signaling 9309
Donkey anti-mouse IgG (H+L) Alexa-Fluor®
488, IHC (1:100)
Dianova 715-454-151
Donkey anti-rabbit IgG (H+L) Alexa-Fluor®
488, IHC (1:100)
Dianova 715-545-152
Donkey anti-mouse IgG (H+L) Cy3, IHC
(1:100)
Dianova 715-166-140
Donkey anti-rabbit IgG (H+L) Cy3, IHC
(1:100)
Dianova 711-165-152
Sheep anti-mouse IgG HRP Linked Whole
Ab, IHC (1:3,000)
GE Healthcare NA931
Donkey anti-rabbit IgG HRP Linked Whole
Ab, IHC (1:3,000)
GE Healthcare NA934
Mouse anti-CD133/1 (AC133)APC, FC
(1:100)
Miltenyi Biotec 130090826




qPCR primers This study Appendix Table S5
Chemicals, enzymes and other reagents
Advanced DMEM/F12 (ADF) Gibco 12634
B27 supplement (50×) Gibco 17504044
BMP2 (human) Gibco PHC7146
Carboplatin Merck 216100
EGF (human) Gibco PHC7146
Fetal calf serum (FCS) Biochrom S0115
FGF-10 (human) PeproTech 100-26-B
GlutaMax (100×) Gibco 35050-038
HEPES (1 M) Gibco 15630-056
L-Glutamine Gibco 25030-024
N2 supplement (100×) Gibco 17502048
Na-pyruvate Sigma-Aldrich S8636
Nicotinamid Sigma-Aldrich N0636
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Reagents and Tools table (continued)







SB431542 (TGF-b inhibitor) Calbiochem 616454
Wnt3a In-house production
CHIR99021 Sigma SML1046
Collagenase type I Sigma C5138
Collagenase type II Biochrom C2-28
Cryo-SFM PromoCell C-29910
DMEM (high glucose, NEAA, no glutamine) Gibco 10938-025
Dulbecco’s phosphate buffered saline (DPBS) Gibco 14190-169
MatrigelTM (basement membrane matrix,
Growth factor reduced)
Corning 356231
TrypLETM Express Gibco 12605-028
Zeocin Gibco R250-01
Acrylamid/Bisacrylamid Roth 3029.1
Amersham Hyperfilm ECL GE Healthcare Life Sciences 28906835
Bovine serum albumin (BSA) Biomol 01400.1
Carboplatin Merck 216100
DRAQ5 (5 mM) Thermo Scientific 65-0880-96
Eosin Y solution Roth 7089.3
FuGENE® 6 Promega E2691
HistoBond® microscope slides Marienfeld 0810000
Mayer’s hematoxylin solution Roth T865.1
Milk powder AppliChem A0830,1000
Mowiol® 4-88 Sigma 81381
Opti-MEMTM Thermo Scientific 31985070
Paraformaldehyde (PFA) Sigma-Aldrich 4441244




PVDF membrane Polyscreen® PerkinElmerTM NEF100200
Roti®-Histokitt Roth 6638.2
TEMED Roth 8142.1
Target retrieval solution (10×) Dako S1699





Adobe Creative Cloud https://www.adobe.com/gr_e
n/creativecloud/desktop-app.
html
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Reagents and Tools table (continued)
















ultraView Universal DAB detection kit Ventana 760-500
CellTiter-Glo® 3D Cell Viability Assay Promega G9681
Two-color Quick-Amp Labeling Kit Agilent Technologies 5190-0444
One-color Low Input Quick Amp Kit Agilent Technologies 5190-2305
4 × 44K whole human genome microarray Agilent Technologies 014850
8 × 60K human custom microarray Agilent Technologies 048908
Lenti-XTM concentrator Clontech 631232
Plasmid Midi Kit QIAGEN 12143
RNeasy Mini Kit QIAGEN 74104
AllPrep DNA/RNA Mini Kit QIAGEN 80204
Quick Ligation Kit NEB M2200
QubitTM dsDNA HS Assay Kit Thermo Fisher Q32851
AB Power SYBR® Green RNA-to-CTTM 1-Step
Kit
Thermo Fisher 4389986
Ventana Benchmark XT Autostainer
instrument
Ventana Medical Systems
SP-8 confocal microscope Leica
TCS SP-E confocal microscope Leica
Western Blot system Bio-Rad
NanoDrop 1000 UV/Vis spectrophotometer Kisker
Agilent 2100 Bioanalyzer Agilent Technologies
G2565CA high-resolution laser microarray
scanner
Agilent Technologies
Paraffin Rotation Microtome HM315 Microm
Tissue processor TP1020 Leica
Megacentrifuge 2.0 R Heraeus Instruments
StepOnePlusTM Real-Time PCR System Applied Biosystems
Sorvall centrifuge and rotor SS34 Sorvall
Master Cycler Gene Amp® PCR System 9700 Thermo Fisher
FACSCantoTM II BD Biosciences
LSRFortessaTM BD Biosciences
FACSAria II BD Biosciences
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Methods and Protocols
Procurement of human material
Approval for the preparation and experimental usage of the primary
material was given by the Ethics Commission of the Charite´, Berlin
(EA1/002/07), and informed consent was obtained from every patient.
Human fallopian tube (FT) samples were provided by the Auguste-
Viktoria-Klinikum Berlin, Department of Gynecology and Obstetrics,
while ovarian cancer samples were received from the Department of
Gynecology, Charite´ University Hospital, Campus Virchow Clinic.
Tissue processing and organoid culture of FT samples
Only anatomically normal fallopian tubes removed by standard
surgical procedures for benign gynecological disease were used for
cell isolation. The tubes were transported and dissected within 2–
3 h of removal. Of each FT sample, one piece was saved for RNA/
DNA preparation.
1 After washing with DPBS and longitudinal opening of the FT
with scissors, the tissue was incubated in collagenase I (Sigma)
for 45–60 min at 37°C for enzymatic detachment of epithelial
progenitors.
2 Subsequently, the mucosal cells were scraped off the muscu-
laris with a scalpel, resuspended in the enzyme solution,
mixed with one volume of ADF supplemented with 1×
GlutaMax and 10 mM HEPES (ADF++), and pelleted by
centrifugation (7 min, 300 × g).
3 Cells were seeded in 2D culture with ADF++ supplemented
with 5% FCS, Pen/Strep, 10 ng/ml hEGF, and 9 lM ROCK
inhibitor (2D medium) for up to 1 week before transfer into
MatrigelTM for organoid formation.
The FT organoids were cultured as described in Kessler et al
(2015).
1 To initiate organoid growth, approximately 30,000 cells,
obtained from 2D culture by incubation with the TrypLETM
enzyme mixture (10 min, 37°C), were seeded in one 50 ll
drop of MatrigelTM per well of an uncoated 24-well plate.
2 The plate was placed in a humidified incubator at 37°C for
30 min to allow the MatrigelTM to polymerize before being
overlaid with 500 ll of a growth factor cocktail stimulating dif-
ferent paracrine pathways including EGF and Wnt signaling.
The detailed composition of the fallopian tube organoid
medium (FTM) is given in Table EV2.
3 Medium was changed every 3–4 days, and organoids were
expanded every 2–3 weeks at a rate of 1:2–1:3.
4 For expansion, organoids were released from MatrigelTM,
washed with ADF++, taken up in pre-warmed TrypLETM, and
incubated for 7–10 min at 37°C for enzymatic digestion.
5 Subsequently, organoids were vortexed three times for 3 s,
washed with ADF++, and pelleted by centrifugation (5 min at
300 × g).
6 Finally, the shredded organoids were resuspended in fresh
MatrigelTM and seeded into pre-warmed cell culture plates
before FTM was added to the organoids.
Tissue processing and organoid culture of ovarian cancer samples
Cancer samples, surgically removed from patients with a prelimi-
nary diagnosis of HGSOC, were retrieved from tumors of specified
sites within the abdominal cavity. The tumor material was trans-
ported and processed within few hours after surgery, and each
sample was divided into three pieces for cell preparation, tissue fixa-
tion, and RNA/DNA isolation.
1 For isolation of HGSOC progenitors, the tissue pieces were
washed with DPBS, minced with a scalpel into very small
pieces, transferred to a 50-ml falcon tube, and incubated in a
1:1 mixture of collagenase I and collagenase II (Sigma) for
around 60 min at 37°C on a shaker.
2 To further separate the cells mechanically, the enzyme-tissue
mixture was vortexed two times for 10 s. Next, one volume of
ADF++ was added and the cell suspension was centrifuged
(5 min, 300 × g, 4°C).
3 The cell pellet was resuspended in ADF++, and cells were
counted using a Neubauer chamber.
4 After initial isolation from the tumor tissue, ovarian cancer
cells were seeded in MatrigelTM at a concentration of approx.
30,000 cells/50 ll.
5 In order to determine growth requirements for HGSOC orga-
noids, isolates were seeded in parallel in different media
compositions to test requirement for selected paracrine niche
factors including BMP and Wnt pathway (Table EV3). The
optimal growth medium for each patient-derived HGSOC orga-
noid line is listed in Table EV3.
6 Upon proper organoid maturation and growth under specified
conditions, they were split at a ratio of 1:3 every 2–3 weeks.
7 For passaging, they were released from MatrigelTM using ice-
cold ADF++, centrifuged at 300 × g for 5 min, and resus-
pended in 500 ll pre-warmed TrypLETM per well. Enzymatic
digestion was carried out for 7 min at 37°C.
8 Afterward, the organoid suspension was vortexed three times
for 3 s, mixed with cold ADF++ at a ratio of 1:1, and centri-
fuged at 300 × g for 5 min.
9 Next, the supernatant was removed, the cell pellet resuspended
in MatrigelTM and seeded into pre-warmed cell culture plates.
After ~ 20 min, the MatrigelTM was overlaid with the respec-
tive medium. The medium was changed twice per week, and
the organoids were kept in a humidified incubator at 37°C and
5% CO2.
Organoid stocks
Organoid stocks were prepared by releasing organoids from ~ 1-
week-old fully formed organoid cultures, by dissolving them from
MatrigelTM in cold ADF, pelleting by centrifugation, and resuspen-
sion in 500 ll of freezing medium CryoSFM. After transfer of the
organoid suspension into cryotubes and a freezing container, stocks
were kept for at least 24 h at 80°C before transfer into liquid nitro-
gen for long-term storage.
Production of Wnt3a- and RSPO1-conditioned medium
Two cell lines stably producing Wnt3a (L Wnt-3a cells) and R-
Spondin 1 (293T HA Rspo1-Fc cells) were used for the production of
conditional medium. The conditioned medium was produced based
on a protocol modified from Willert et al (2003) and Farin et al
(2012). In brief, cells were defrozen and seeded in DMEM with 10%
FCS. The cells were passaged and selected with Zeocin (Invitrogen)
at a final concentration of 125 lg/ml. After at least 5 days of selec-
tion, fresh DMEM with only 5% FCS was added. Upon incubation
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for another 4–5 days, the supernatant was collected, centrifuged
(1,200 × g for 10 min), filtered through a Steritop bottle (0.22 lm),
aliquoted, and stored at 20°C. Conditioned medium from the
parental L cell line was produced as a control in the same way, only
without Zeocin selection. To determine the Wnt activity of the
conditioned medium, the supernatants were added to a Wnt
reporter cell line (293T WntR), which turns green, due to insertion
of a plasmid carrying the GFP gene under control of a Wnt respon-
sive element (7xTcf-eGFP; Addgene 24304; Fuerer et al, 2010). The
quality of the conditioned medium was evaluated depending on the
quantity and intensity of the GFP signal.
Cloning of shRNAs and virus production
To obtain stable knockdowns of PTEN and RB, shRNA sequences
targeting specific regions within the respective mRNA (in-house-
designed) were cloned into the lentiviral vector, pLVTHM, carry-
ing mCherry, or GFP as mammalian selection marker (Appendix
Table S5). Also, a shRNA against Luciferase cloned into
pLVTHM-mCherry and-GFP was included as a control. The retro-
viral vector with the shRNA against p53 was provided by Alexan-
der Loewer. Cloning and virus production involved the following
steps:
1 The pLVTHM-GFP or pLVTHM-mCherry vectors were digested
by Clal/Mlul (NEB) enzymatic restriction.
2 Sense and antisense oligos (target sequence with specific over-
hangs to generate hairpin structure; Appendix Table S4) were
annealed using the following program in a thermocycler: (i)
94°C—4 min; (ii) 70°C—10 min; 70°C—1 s; (iii) 99 cycles of
69.9°C—1 s, 69.8°C—1 s, 69.7°C—1 s, 69.6°C—1 s; (iv) 20°C
—99 s; (v) 10°C—60 s; and (vi) 4°C. Annealed oligos were
diluted 1:200 in water.
3 Ligation of the linearized vector and annealed oligos was
performed using the Quick ligation kit (NEB).
4 The ligation mix was transformed into chemically competent
E.coli Stbl3 by incubation for 20 min on ice, 2 min at 42°C,
and 2 min on ice. After addition of 200 ll of LB medium, the
bacteria were incubated for 1 h at 37°C on a shaker and the
bacterial suspension was transferred to a LB agar plate supple-
mented with 100 mg/ml ampicillin and incubated ON at 37°C.
5 After successful transformation, bacterial clones were picked
and grown in an ON culture. The next day, a plasmid prep
(QIAGEN) and bacterial stocks were prepared.
6 To ensure that the oligos were inserted correctly into the plas-
mid, a control digestion with KpnI/EcoRI (NEB) enzymes was
performed (30 min at 37°C).
Replication-deficient retroviral (RV) and lentiviral (LV) particles
were produced by transient transfection of HEK 293T in 10-cm
dishes:
1 Specific amounts of viral target plasmids (2.6 lg) as well as
retro- and lentiviral packaging (1.95 lg) and envelope plas-
mids (0.65 lg) were mixed with Opti-MEMTM (Thermo Scien-
tific) to achieve a final volume of 52 ll.
2 Next, a mixture of Opti-MEMTM and FuGENE 6 (Promega)
was added to the plasmids and incubated for 20–30 min at
RT.
3 The formed liposomes were added dropwise to HEK 293T
cells (~ 75% confluence) in 1×DMEM (supplemented with
2 mM L-glutamine, 1 mM Na-pyruvate, and 10% FCS).
4 The next day (~ 12 h), the transfection medium was aspirated
and fresh medium added.
5 Around 36–48 h post-transfection, the viral supernatant was
collected, filtered (0.45 lm), and concentrated with Lenti-XTM
concentrator (Clontech).
6 The viral pellet was resuspended in ADF medium to achieve
10× concentrated virus. Aliquots were stored at 80°C.
Genetic manipulation of primary cells
1 Freshly isolated FTECs in 2D culture of an early passage (p0/
p1) were transduced when reaching around 50–70% conflu-
ence with 1× concentrated retrovirus, carrying the p53 shRNA
and puromycin selection marker, which was diluted in trans-
duction medium (ADF++ supplemented with 5% FCS, 10 ng/
ml hEGF, and 5 lg/ll polybrene (Sigma)).
2 The cells were incubated for 12–18 h with the virus. The next
day, the supernatant was removed and fresh 2D medium was
added to the cells.
3 When the cultures reached 80–90% confluence, they were split
with TrypLETM and seeded back into 2D at a ratio of 1:3.
4 In the next passage, the lentivirus carrying the PTEN shRNA
and mCherry selection marker was added to the cells at 50–
70% confluence in transduction medium. The cells were split
again when reaching 90% confluence.
5 Cells were further sequentially transduced with the third
viral vector carrying the shRNA against RB and the GFP
selection marker. After culture reached 80–90% confluence
in maximum passage 3, successfully transduced cells were
selected.
6 To retrieve cells carrying a fluorescent selection marker,
FACS was performed. For this purpose, the primary cells
were detached using TrypLETM (~ 10 min), pelleted by
centrifugation (5 min, 300 × g), resuspended in FACS buffer
(1×DPBS with 1% FCS, 1% HEPES, and 3% ROCK inhibitor),
and passed through a 35-lm cell strainer into polystyrene
tubes.
7 Propidium iodide (Sigma) was added shortly before FACS to
exclude the dead cells. Sorting was performed by the Flow
Cytometry Core Facility (DRFZ, Charite´platz 1, 10117 Berlin)
using the FACSAria II (BD). The GFP and mCherry single- or
double-positive cells were collected in polystyrene tubes
supplied with 2D medium (ADF with Glutamax, HEPES, 5%
FCS, Pen/Strep, hEGF, and ROCK inhibitor).
8 Collected cells were centrifuged directly after FACS and seeded
in 3D culture with around 1.5 × 105 cells/50 ll MatrigelTM.
Cells transduced with the retroviral vector carrying the p53
shRNA were selected by adding 0.5 lg/ml puromycin (Gibco)
for 10 days to the respective cell culture.
Single-cell preparation and flow cytometric analysis
1 To prepare single cells, organoids were released from Matri-
gelTM using cold PBS and pelleted by centrifugation (5 min,
300 × g).
2 The organoid pellet was resuspended in TrypLETM and incu-
bated for 15–20 min at 37°C.
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3 After enzymatic treatment and vortexing (three times for 6 s),
the organoid fragments were further mechanically disrupted
by passing 3–4× through a needle (26G).
4 Next, the cells were taken up in ADF++ and passed through
a 40-lm filter. The single-cell suspension was pelleted and
washed by addition of 1% BSA/PBS.
5 The cells were stained in 2% BSA/PBS. Staining was
performed for 10–30 min at 4°C in the dark. Finally, the cells
were washed and resuspended in 1× PBS.
6 Flow cytometric analysis was performed using a FACSCantoTM
II (BD) or LSRFortessaTM (BD) flow cytometer and the FlowJo
vX.0.6 software.
Luminescent cell viability assay
To quantify the number of viable cells within one organoid well,
the CellTiter-Glo 3D Cell Viability Assay (Promega) was applied.
According to the manufacturers’ protocol, the organoids were
lysed with the CellTiter-Glo 3D reagent and the luminescence
was measured within 30 min after the start of the reaction using
black 96-well plates (Costar, Corning) and a standard plate
reader.
Immunohistochemistry of HGSOC tissue
Paraffin-embedded tumor samples in 5-lm sections were stained
with antibodies against EpCam (Thermo Scientific), p16 (NeoMark-
ers), p53 (Dako), and Pax8 (Sigma) on the Ventana Benchmark XT
Autostainer instrument. 3,30-diaminobenzidine peroxide substrate
(DAB+) of the ultraView Universal DAB Detection Kit was used as
a chromogen. The antibodies are well-established in the diagnostic
routine laboratory, and signals were strong and clearly discernable.
Fixation, embedding, and immunofluorescence staining of organoids
and tissue
For fixation, organoids were released from MatrigelTM and incubated
in 3.7% PFA for ~ 1 h at RT, while tissue pieces were incubated in
PFA for ~ 24 h at RT. Organoids and tissues were then dehydrated
and paraffinized. For dehydration, organoids were passed manually
through an alcohol dilution series: 60% EtOH (20 min, RT), 75%
EtOH (20 min, RT), 90% EtOH (20 min, RT), abs. EtOH (20 min,
RT), 100% isopropanol (20 min, RT), and 2 × 100% acetone
(20 min, RT). Tissue pieces were transferred to the Shandon Citadell
1000 rondell for automatic dehydration. After dehydration, orga-
noids and tissue pieces were embedded in paraffin, sectioned at
5 lm with a microtome (Microm), and collected onto microscope
slides (Marienfeld).
Prior to staining, the formaldehyde-fixed paraffin-embedded
(FFPE) organoids and tissues were deparaffinized by applying a
series of decreasing alcohol concentrations: xylene (2 × 10 min),
100% ethanol (2 × 2 min), 90% ethanol (1 × 2 min), 70% ethanol
(1 × 2 min), 50% ethanol (1 × 2 min), and H2O (2 × 2 min). For
antigen retrieval, the slides were incubated for 30 min at 98°C in 1×
Target retrieval solution (Dako). Sections were stained by adding
primary antibodies diluted in immunofluorescence buffer (IFB: 1%
BSA, 2% FCS, and 0.1% Tween-20 in 1×PBS) and depending on the
antibody incubated for 90 min at RT or overnight at 4°C in a humid-
ified chamber. After washing 5 × 5 min with 1× PBS supplemented
with 0.05% Tween-20, the respective secondary antibodies diluted
in IFB together with the nucleic acid dye DRAQ5 or Hoechst were
added to each section and incubated for 60 min at RT. Subse-
quently, the slides were washed and sections mounted with cover-
slips using Mowiol.
Hematoxylin and eosin staining
Before staining with hematoxylin and eosin (HE), organoid slices
were deparaffinized as described above. After deparaffinization, the
sections were covered completely with Mayer’s haematoxylin solu-
tion (Roth) and incubated for 15 min at RT. The slides were rinsed
with ddH2O and tap water. Subsequently, the sections were covered
with Eosin Y solution (1% aqueous, Roth) and incubated for 10 min
at RT. Finally, slides were rinsed for 1 min with ddH2O and embed-
ded using Roti-Histokitt.
Quantitative reverse transcription–PCR (qRT–PCR)
The AB Power SYBR Green RNA-to-CTTM 1-Step Kit (Thermo
Fisher) was applied to perform reverse transcription and quantita-
tive PCR in one step. RNA was added in a volume of 10 ll at a
concentration between 2 and 10 ng/ll. qRT–PCR was performed
using the StepOnePlusTM Real-Time PCR System (Applied Biosys-
tems) with the following program: (i) 30 min, 48°C; (ii) 10 min,
95°C; (iii) 15 s, 95°C; and (iv) 1 min, 60°C. Steps 3 and 4 were
repeated 40 times. For each primer pair and RNA-sample, the
reaction was done in triplicate. The amplification plots obtained
from the qRT–PCR were analyzed with the StepOneTM Software
(version 2.3; Thermo Fisher). The expression levels were rela-
tively quantified by calculating DDCt, and the expression of the
target genes was always normalized to the expression of the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
Western blotting
For the purpose of sample collection, organoids were washed with
DPBS, pelleted, and lysed by addition of 1× Laemmli buffer and
heating for 10 min at 95°C. After the proteins were separated
according to their molecular weight by performing SDS–PAGE, they
were transferred from the gel to a PVDF membrane using a Mini
Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) and applying
250 mA, 400 V, and 4°C under constant stirring for 2.5 h. After
blocking in a 1:1 mixture of 5% milk and 5% BSA, the membrane
was incubated at 4°C overnight with the primary antibody. The next
day, the membrane was washed 3 × 10 min in TBS-0.1% Tween-
20. Subsequently, the membrane was incubated for 1 h at RT with
the respective conjugated secondary antibody. After washing, the
membrane was covered with chemiluminescence reagents (Perkin
Elmer). Using Hyperfilm (Amersham Biosciences) and a developer
machine, the proteins were visualized. The housekeeping gene b-
actin was used as the internal control for normalization of protein
loading.
DNA and RNA isolation
DNA of tissue and organoids was isolated using the AllPrep DNA/
RNA Mini Kit (QIAGEN) according to manufacturers’ protocol. DNA
purifications were quantified by measuring optical density at 260-
nm wavelengths.
RNA from cells of 3D cultures was isolated using the RNeasy
Mini Kit (QIAGEN) or the AllPrep DNA/RNA Mini Kit (QIAGEN).
RNA from tissue samples was isolated using the AllPrep DNA/
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RNA Mini Kit (QIAGEN). After pelleting the organoids, they were
lysed in the respective sample buffer and RNA purification was
performed according to the manufacturer’s protocols. RNA
concentration and purity were measured with a NanoDrop ND-
1000 Spectrophotometer.
For microarray analysis, total RNA was isolated with TRIzol (Life
Technologies) according to the supplier’s protocol using glycogen as
carrier. Quality control and quantification of total RNA were carried
out using the NanoDrop 1000 UV-Vis spectrophotometer (Kisker) as
well as the Agilent 2100 Bioanalyzer with a RNA Nano 6000
microfluidics kit (Agilent Technologies).
Drug testing
To test the response of patient-derived HGSOC organoids to the
chemotherapeutic drug carboplatin (Merck), organoids were dissoci-
ated into single cells by using enzymatic (TrypLETM, 15 min, 37°C)
and mechanical (vortexing and passing through 26G needle) disrup-
tion. Subsequently, cells were counted and seeded at 15,000 cells/
25 ll MatrigelTM into a 48-well plate. After maturation of organoids
(~ 7–10 days in culture), treatment with carboplatin with a concen-
tration range between 0 and 100 lg/ml was started. At 1 week post-
treatment, cell viability was determined as described above.
Microarrays (dual-color and single-color)
Microarray experiments were performed as dual-color or single-
color hybridizations on either Agilent Whole Human Genome
4 × 44K microarrays (Design ID 014850) or 8 × 60K human custom
(Agilent-048908) microarrays comprising identical features for
coding genes. Color-swap dye-reversal hybridizations were
performed in order to compensate for dye-specific effects and to
ensure statistically relevant data when using small sample sizes.
RNA labeling was done either with a two-color Quick Amp Labeling
Kit (4 × 44K arrays) or with a one-color Low Input Quick Amp Kit
(8 × 60K arrays) according to the supplier’s recommendations (Agi-
lent Technologies).
In brief, mRNA was reverse transcribed and amplified using an
oligo-dT-T7 promoter primer and the T7 RNA polymerase. The
resulting cRNA was labeled with only Cyanine 3-CTP (single-color)
or with Cyanine 3-CTP and Cyanine 5-CTP (dual-color). After
precipitation, purification, and quantification, 1 lg (4 × 44K arrays)
or 300 ng (8 × 60K arrays) of each labeled cRNA was fragmented
and hybridized to whole-genome multipack microarrays according
to the manufacturer’s protocol (Agilent Technologies). Scanning of
microarrays was performed with 5-lm resolution and XDR extended
range (4 × 44K arrays) or 3-lm resolution (8 × 60K arrays) using a
G2565CA high-resolution laser microarray scanner (Agilent Tech-
nologies). Microarray image data were analyzed and extracted with
the Image Analysis/Feature Extraction software G2567AA v.
A.11.5.1.1 (Agilent Technologies) using default settings and either
the GE2_1100_Jul11 (dual-color) or the GE1_1105_Oct12 (single-
color) extraction protocol.
For analysis of dual-color microarrays, the extracted MAGE-ML
files were processed with the Rosetta Resolver, Build 7.2.2 SP1.31
(Rosetta Biosoftware). Ratio profiles comprising single hybridiza-
tions were combined in an error-weighted fashion to create ratio
experiments. A 1.5-fold change expression cut-off for ratio experi-
ments was applied together with anti-correlation of ratio profiles,
rendering a highly significant, robust and reproducible microarray
analysis (P-value < 0.01). Additionally, raw data txt files were
analyzed with R packages from the Bioconductor repository.
The extracted single-color raw data files were background
corrected, quantile normalized, and further analyzed for differential
gene expression using R 3.4 (Ritchie et al, 2015). Microarray gene
expression comparisons between groups and the associated BioCon-
ductor package LIMMA were performed using unpaired tests for all
human comparisons (R Core Team, 2013).
All microarray data have been deposited in the Gene Expression
Omnibus (see Data availability section).
Capture of the targeted disease-related genome and
next-generation sequencing
A SureSelectXT Automation Custom Capture Library (Agilent) target
enrichment panel was designed. The enrichment panel comprised
all coding exons of 121 genes associated with ovarian cancer
(Table EV3). Capture was performed according to the manufac-
turer’s instructions using an NGS Workstation Option B (Agilent)
for automated library preparation starting with 3 lg DNA per
sample. Sequencing was performed on an Illumina HiSeq 2500
system generating 2 × 100 bp paired-end reads with a target cover-
age of > 200-fold per sample. Sequence reads were mapped to the
haploid human reference genome (hg19) using BWA. Single nucleo-
tide variants (SNVs) and short insertions and deletions (indels) were
called using FreeBayes v1.1. (preprint: Garrison & Marth, 2012).
Sequencing data were deposited at the European Genome-phenome
Archive (see Data availability section).
Variants called by FreeBayes were filtered for quality
(QUAL > 10, coverage > 50) and annotated by SnpEff v4.3k (Cin-
golani et al, 2012) and Annovar (Wang et al, 2010). For each vari-
ant, the effect with the highest impact as defined by SnpEff was
selected. Variants were flagged as rare if they showed < 1% popula-
tion frequency in the 1,000 genome (Auton et al, 2015) and
ESP6500 (Exome Variant Server, NHLBI GO Exome Sequencing
Project (ESP), Seattle, URL: http://evs.gs.washington.edu/EVS/;
accessed 2014-12) data sets. Predictions of amino acid exchange
effects on protein function from MetaSVM, MetaLR, and M-CAP as
provided by Annovar were used to assess loss of function.
Statistical analysis
Unless otherwise stated, two-sided Student’s t-test was applied to
determine statistical significance between two experimental groups
and results are presented as the mean  SEM (standard error of the
mean) or mean  SD (standard deviation). Analysis was performed
with GraphPad Prism 7.03. A P-value ≤ 0.05 was considered statisti-
cally significant.
Data availability
All microarray data have been deposited in the Gene Expression
Omnibus (GEO; www.ncbi.nlm.nih.gov/geo/) of the National Center
for Biotechnology Information and can be accessed with the GEO
accession numbers GSE125883 and GSE124766. Sequence data have
been deposited at the European Genome-phenome Archive (EGA)
under accession number EGAS00001003821 (https://www.ebi.ac.uk/
ega/studies/EGAS00001003821). All code used for generating
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analyses in this publication is available from https://github.com/
MPIIB-Department-TFMeyer/Hoffmann_et_al_Ovarian_Cancer_Orga
noids.
Expanded View for this article is available online.
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